Pfizer Settles $345m EpiPen Consumers Suit, But Viatris Marches On
Suit Against Viatris’ Mylan Was Set For 7 September
After “four years of vigorous litigation,” Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan “to monopolize the market” for the EpiPen autoinjector device.
